Clinical Trials
4 trialsNCT00640978 2025-05-01
Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01784861 2021-07-08
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
Washington University School of Medicine
Phase 1/2 Terminated
NCT00409292 2014-08-11
RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00363051 2013-05-10
Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
Novartis
Phase 2 Completed